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Summary Objectives: The aim of this study was to assess the performance of four
demand oxygen delivery systems (DODS) in improving oxygenation and effort
tolerance, at rest and during exercise, in chronic obstructive pulmonary disease
(COPD) patients.
Materials and methods: Thirteen COPD patients were prospectively included. Four
DODS (Oxiclip, Versatile, Venture and Impulse) were compared with continuous-flow
oxygen (CFO).Nine of these patients performed 6-min walking tests on room air and
on 3 l/min oxygen by DODS and CFO; Oxygen saturation, walking distance and the
Borg dyspnea score were recorded.
Results: With all four DODS devices arterial oxygenation was improved with lower
oxygen flow rates than with CFO. Oxygen economy was best with Impulse, but at a
cost of less satisfactory oxygenation. Exercise desaturation was similar with CFO,
Oxiclip, Venture, and Impulse but significantly higher with Versatile (Po0.05). Borg
dyspnea scores were similar with CFO, Oxiclip, Venture, and Versatile but worse with
Impulse (Po0.05). There was no significant difference in walking distances.
Conclusions: All four DODS improved oxygen saturation and saved oxygen.
However, performance was better with the two devices (Oxiclip and Venture) that
deliver a bolus of oxygen at inspiration onset.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Long-term oxygen therapy improves survival in
patients with chronic obstructive pulmonary dis-
ease (COPD) provided that oxygen is delivered at
least 15 h per day.1,2 Use of a portable oxygen
delivery system allows patients to increase their
daily treatment duration while continuing to be
active. Several studies have shown that use of
portable systems improves compliance with oxygen
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therapy.3 Because oxygen cylinders are heavy and
have limited autonomy, oxygen-conserving strate-
gies have been developed. One such strategy is use
of a demand oxygen delivery system (DODS).4
DODS, however, are not still widely used, and their
potential effectiveness in hypoxemic patients with
chronic obstructive pulmonsry disease (COPD) is
poorly documented.
DODS take advantage of the fact that oxygen is
needed only during the initial phase of inspiration.
DODS stop the flow of oxygen throughout expira-
tion. During inspiration, some models deliver a
brief initial pulse only, others a brief initial pulse
followed by a constant flow, and yet others a
constant flow throughout inspiration. The volume
and duration of the oxygen pulse varies across
devices. These differences may translate into
differences in arterial oxygenation in a given
patient. Moreover, the efficacy of DODS may vary
among patients, across clinical conditions, and
according to whether use occurs at rest or during
exercise; also, DODS settings must be tailored to
each patient before use.5,6
The aim of this study was to compare the efficacy
of four DODS at rest and during exercise in
improving oxygenation and exercise tolerance in
patients with COPD.
Methods
The study concerned 13 patients with severe stable
COPD, characterized by FEV1 less than 50%, PaO2
less than 65mmHg on room air, and no exacerba-
tions within 3 months before the study. All patients
were current or former smokers. Patients with
severe comorbidity (cardiovascular disease or other
organ system involvement) or a contraindication to
exercise testing (lower-limb arterial disease) were
excluded. All patients tolerated room air. Patients
gave informed consent, and the study was approved
by the appropriate ethics committee.
The four DODS used in this study differed in some
of their characteristics (Table 1). With Oxiclip
(Nellcor Puritan Bennett), an initial 12-ml pulse is
followed by adjustable constant flow throughout
inspiration. Venture (Invacare) delivers an initial
oxygen pulse followed by adjustable constant flow
during the first second of each inspiration. Those 2
devices are similar in their flow profiles, but initial
pulse is higher and delivery is stopped by end of
inspiration with Oxiclip while with Venture delivery
is stopped after 1 s. Versatile (De Vilbiss) delivers
constant-flow oxygen at a rate of 10-l/min during
initial inspiration; duration of oxygen delivery can
be set between 0.05 and 0.6 s. Impulse (Airsep)
delivers a fixed amount (25–28ml) of constant-flow
oxygen during the first 200ms of inspiration; the
delivery rate can be set between 14 and
1
1 of the
inspiratory rate. To select DODS settings, we used
the continuous-flow equivalents recommended by
the manufacturer of each device. Methods of
calculation of ogygen output of each device
averaged per minute are shown in the annex.
For blood gas measurements at rest, a catheter
was inserted into the brachial artery under local
anaesthesia. The patients received CFO or oxygen
via each DODS, in random order. A standard nasal
catheter was used for all five modalities. Duration
of testing was 10min per modality. Each device was
tested at three constant-flow equivalents, namely,
1, 2, and 3 l/min, in that order. Arterial blood gases
were measured on room air before oxygen delivery
and at the end of each 10-min oxygen delivery
period. The tests with each modality were sepa-
rated by 20-min washout periods.
In nine of the 13 patients, 6-min standardised
walking tests were performed as previously de-
scribed,7 and walking distance was recorded. Of
the four other patients, two were unwilling to
undergo further testing and two were too tired for
a walking test. In order to compare DODS efficacy
according to their technical characteristics (with-
out taking the oxygen source weight into account),
the patients did not carry the oxygen cylinder.
Walking tests were performed first on room air,
then with CFO at 3 l/min and each of the 4 DODS at
a 3 l/min constant-flow equivalent, in random
order. Patients rested for at least 20min between
walking tests. Oxygen saturation was recorded
before and at 1-min intervals during each walking
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Table 1 Demand Oxygen Delivery Systems specifications.
Oxiclip Versatile Venture Impulse
O2 source input Liquid Liquid Gaseous Gaseous
Valve supply Pneumatic Electric Electric Electric
Power – 2 1.5 V Internal battery 2 1.5 V
Weight, g 142 227 411 350
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test. Respiratory rate, heart rate, and blood
pressure were recorded before and at the end of
each walking test and the Borg dyspnea score 8 at
the end of each test.
Statistical analysis
Values are reported as means7 standard deviation
(SD). Analysis of variance for repeated measures
was used to compare groups. Statistical significance
was defined as Po0.05. Data were analysed using
Statisticas Software.
Results
The characteristics of the 13 patients (11 men and 2
women) are shown in Table 2.
We first calculated the real oxygen flow rate
delivered by each DODS at oxygen-flow numerical
settings of 1, 2, and 3 l/min. The real oxygen flow
rates calculated from the DODS characteristics and
respiratory rate (and the inspiration/expiration
ratio for Oxiclip) in each patient at rest are
reported in Table 3. All DODS saved oxygen
(Po0.001), and saving was significantly different
across device (Po0.001).
We then measured the PaO2 at rest obtained with
each device at three oxygen-flow numerical set-
tings and with the CFO level corresponding to the
constant-flow equivalents claimed for those set-
tings. With all four devices, PaO2 increased
significantly from one oxygen-flow numerical set-
ting to the next (Fig. 1). This increase differed
significantly across devices (two-way ANOVA,
Po0.000001). PaO2 achieved with Oxiclip and
Venture were not significantly different from PaO2
achieved with CFO at all three settings. Versatile
gave PaO2 values not significantly different from
CFO at 1 and 2 l/min but a significantly lower value
at 3 l/min (Po0.01). Impulse yielded significantly
lower PaO2 values than CFO at both 2 l/min
(Po0.001) and 3 l/min (Po0.0001). PCO2 increased
significantly from one oxygen-flow numerical set-
ting to the next (Po0.001), with no differences
across modalities (data not shown).
Fig. 2 shows the mean PaO2 values achieved at
rest according to the calculated oxygen flow rates
at each setting. With all four DODS devices, arterial
oxygenation was improved with lower oxygen flow
rates than with CFO. Oxygen economy was best
with Impulse, but at a cost of less satisfactory
oxygenation.
Exercise tests
On room air, the mean SaO2 decrease during the
6-min walking test was 6.374.3% and the mean
walking distance was 254794m. Borg dyspnea
scale on room air was 3.8672.61. Walking distance
was not affected by the order of oxygen delivery
modalities (which was random). As shown in Table 4,
Versatile produced significantly higher desaturation
than CFO (Po0.01), Oxiclip (Po0.01), Venture
(Po0.01), and Impulse (Po0.05). Impulse yielded
a worse Borg dyspnea score than CFO (Po0.01),
Oxiclip (Po0.01), and Versatile (Po0.05). Heart
rate and respiratory rate showed significant in-
creases (Po0.0001 and Po0.05, respectively) with
exercise, of similar magnitude with all devices. Six-
minute walking distance did not differ significantly
across devices.
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Table 2 Patient characteristics.
Mean 7 SD
Age (years) 61.879.8
FEV1ml (%predicted) 10017251
35.5711.6
TLC (ml) (%predicted) 657271478
106.8716.6
FEV1/FVC 46.4716.6
PO2 (mmHg) 60.074.9
PCO2 (mmHg) 44.078.1
pH 7.4070.01
FEV1 : Forced expiratory volume in 1 s.
TLC: Total lung capacity.
FVC: Forced vital capacity.
Table 3 Calculated oxygen flow at each of the three tested oxygen-flow numerical settings.
Numerical setting (l/min) Calculated oxygen flow (l/min)
Oxiclip Versatile Venture Impulse
1 0.33970.061 0.41570.100 0.27470.066 0.11270.027 Po0.001
2 0.87270.180 0.78070.188 0.54870.132 0.22470.054 Po0.001
3 1.41670.316 1.09670.264 0.79770.192 0.33670.081 Po0.001
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Discussion
In our study, at rest as well as during exercise, two
devices (Oxiclip and Venture) were significantly
more effective (i.e. yielded satisfactory oxygena-
tion). Differences across devices could be ex-
plained by delivered oxygen flow profiles. Indeed,
these two DODS deliver an oxygen pulse at the
onset of inspiration, although the volume of this
pulse is larger with Venture. Thus our findings
suggest that improvement in arterial oxygenation
may be more closely dependent on the oxygen
delivery profile than on the volume of oxygen
delivered. This is consistent with earlier studies.
Robert et al.9 studied three flow profiles with the
same valve and found that an initial oxygen surge at
the beginning of inspiration followed by a lower
flow was more effective than a constant flow
throughout the period of valve opening. Tiep
et al.10 reported that efficacy of a pulsed DODS
was increased by earlier delivery of the pulse,
which was as effective as transtracheal oxygen
administration. This suggests that the initial part of
the pulse may play a key role by delivering oxygen
into and across the anatomical dead space. Braun
et al. also found significant differences in the
ability of five DODS to maintain SaO2 during
exercise;11 efficacy was better with the devices
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Figure 1 PaO2 obtained with each device and continuous flow oxygen at three oxygen-flow numerical settings.
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Figure 2 PaO2 values achieved according to the calculated oxygen flow rate delivered by each DODS at each of the
three tested oxygen-flow numerical settings.
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that increased oxygen delivery with respiratory
rate or delivered an oxygen pulse during early
inspiration, as compared to devices that delivered
constant flow during inspiration. In an evaluation of
DODS with a mechanical lung model,12 the amount
of oxygen delivered by CFO decreased as respira-
tory rate increased, whereas DODS delivered the
same oxygen volume at all respiratory rates. As in
our study, pulse delivery was more effective in this
mechanical model than continuous delivery.
Evaluations of DODS efficacy during exercise
testing have yielded conflicting results. Most
studies found that oxygenation was similar with
DODS and CFO in COPD patients.4,6,11,13–16 Carter
et al investigated DODS in patients with restrictive
lung disease (pulmonary fibrosis) and found that
efficacy was good during rest and exercise, despite
severe hypoxemia, high respiratory rates, and high
inspiration over expiration ratios.17 Nevertheless,
Roberts et al.18 and Segard et al.19 reported that
DODS failed to provide adequate oxygenation
during exercise. Differences across patients have
been reported 6,15,19 but not explained. No differ-
ences in functional characteristics across patients
with and without a good response were noted.
However Roberts reported that desaturation during
exercise with a DODS was more severe in patients
with lower baseline SaO2 values.
18 We found no
differences in exercise desaturation profiles across
patients.
In our study the patients did not carry the
equipment, as they would do in normal conditions
of use. However, the aim of this study was to
compare the different DODS on the basis of their
intrinsic characteristics. If we had opted to ask the
patients to carry their oxygen bottle, this would
have disfavoured the systems equipped with valves
functioning with heavier bottles of gaseous oxygen
and prevented us from distinguishing between the
effect related to the valve and that linked to the
weight of the material. Of the two valves showing
the best performances, one functions with liquid
oxygen (Oxiclip) and the other with gaseous oxygen
(Venture). In normal conditions of ambulatory use,
Oxiclip would probably give better results.
With CFO, SaO2 increased linearly with the
oxygen flow rate. Differences across devices could
also be explained in part by the fact that the
continuous-flow oxygen equivalents claimed by the
manufacturers could have been overestimated.
However we chose to do a pragmatic study, using
adjustments as in clinical practice. Thus Impulse
produced about 80% oxygen savings at all three
tested settings but was significantly less effective
in oxygenating the arterial blood. In contrast, two
DODS (Oxiclip and Venture) produced a sharp
increase in SaO2 at the lowest tested oxygen flow
rate and smaller further increases at the two higher
oxygen flow rates. One consequence of this non-
linear pattern was that these two devices yielded
80% oxygen savings at the lowest oxygen flow rate
but only 50% at the higher flow rates.
However other characteristics must be pointed
out. Impulse delivers oxygen only during one in
four, three, or two inspirations, respectively, giving
the patient an unpleasant feeling of insecurity
(possibly responsible for low dyspnea scale scores).
Concerning Versatile, the valve occasionally failed
to trigger, also producing a feeling of insecurity in
the patient.
This study had a number of limitations. First, the
study population was small. However, the results
are statistically significant, and are coherent with
each other and with the functional principle of
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Table 4 Walking test results.
Device Room air CFO Oxiclip Versatile Venture Impulse
Rest values
SaO2 (%) 9073.6 94.472.3 94.272.3 94.972.2 94.772.5 93.972.7 NS
Respiratory rate (/min) 17.173.7 18.274.1 18.173.9 18.273.7 17.573.9 17.974.3 NS
Heart rate (/min) 94 715.2 90.9714.4 87.1720.6 90.5712.2 91.1715.2 91.5714.9 NS
Absolute variation
DSao2 (%) 6.374.3 5.276.7 5.376.8 8.178.3 5.475.4 5.977.1 Po0.01n
D RR (/min) 3.173.9 1.673.5 2.972.2 2.472.3 2.572.5 2.472.0 NS
D HR (/min) 1775.4 14.377.5 19.4711.3 16.275.9 16.177.3 15.477.3 NS
6-min walking distance 253794 257793 260793 2677100 253785 257788 NS
Borg dyspnea score 3.872.6 2.0671.08 2.1271.21 2.3171.38 2.5071.31 3.1271.35 Po0,001w
nANOVA Po0.01, Scheffe post hoc comparison: Versatile produced significantly higher SaO2 than CFO (Po0.01), Oxiclip
(Po0.01), Venture (Po0.01), and Impulse (Po0.05).
wANOVA Po0.001, Scheffe post hoc comparison: Impulse produced significantly higher SaO2 than CFO (Po0.01), Oxiclip
(Po0.01), and Versatile (Po0.05).
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each system; the two most effective valves were
those providing an initial pulse. Given the some-
what heavy methodology chosen, and particularly
the need for repeated exercise tests, patients were
selected on the basis of a PaO2 below 65mm Hg,
which is higher than the usual value indicating long-
term oxygen therapy. However, there is no reason
to think that different results would have been
obtained in more severely hypoxic patients. Finally,
regarding the exercise results, the clinical rele-
vance of the observed differences in saturation is
difficult to determine, and would require long-term
studies of patients using these devices.
Little is known about the long-term safety and
efficacy of DODS. In a study of patients with chronic
hypoxemia who used a DODS or CFO for 1 month,
daily oxygen use was 48% lower with the DODS than
with CFO,6 and overall efficacy was good. No other
long-term efficacy and safety data are available.
Nocturnal oxygenation seems satisfactory.6,13,20
Similar sleep quality with DODS and CFO has been
reported, with the DODS providing 60% oxygen
savings.5 Some patients report being bothered by
the noise made by the device and/or by an
unpleasant feeling caused by the nasal oxygen
pulse.6 Some of our patients found that the noise
was embarrassing, particularly during social activ-
ities.
Conclusion
All four DODS improved oxygen saturation and
saved oxygen. However, the two devices (Oxiclip
and Venture) that deliver a bolus of oxygen at
inspiration onset are most effective. A long-term
study of the efficacy of these oxygen delivery
devices is now required.
Appendix.
For each patient, the oxygen output of each device
averaged per minute at rest was calculated from
DODS characteristics, the respiratory rate (RR) and
the inspiration/expiration ratio, as follows:
Oxiclip: Calculated oxygen flow ¼ [initial pulse
þ (inspiration lengthFpulse length)  a]  RR.
Initial pulse ¼ 12ml (constant), pulse length ¼
0.06 s (constant), a ¼ 4ml for setting 1 l/min,
19.3ml for setting 2 l/min, 34.9ml for setting 3 l/
min.
Venture: Calculated oxygen flow ¼ b  RR. b ¼
16.5ml for setting 1 l/min, 33ml for setting 2 l/
min, 48ml for setting 3 l/min.
Versatile: Calculated oxygen flow ¼ c  RR.
c¼ 25ml for setting 1 l/min, 47ml for setting 2 l/
min, 66ml for setting 3 l/min.
Impulse: Calculated flow rate ¼ 27  RR 
delivery rate. Delivery rate ¼ 14 for setting 1 l/min,
1
2 for setting 2 l/min,
3
4 for setting 3 l/min.
References
1. Nocturnal Oxygen Therapy Trial Group. Continuous or
nocturnal oxygen therapy in hypoxemic chronic ob-
structive lung disease: a clinical trial. Ann Intern Med
1980; 93:391–8.
2. Report of the Medical Research Council Working Party. Long
term domiciliary oxygen therapy in chronic cor pulmonale
complicating chronic bronchitis and emphysema. Lancet
1981;1:681–5.
3. Vergeret J, Brambilla C, Mounier L. Portable oxygen
therapy: use and benefit in hypoxaemic COPD patients on
long-term oxygen therapy [published erratum appears in Eur
Respir J 1989;2:292]. Eur Respir J 1989;2:20–5.
4. Tiep BL, Lewis MI. Oxygen conservation and oxygen-
conserving devices in chronic lung disease. A review. Chest
1987;92:263–72.
5. Cuvelier A, Muir JF, Czernichow P, et al. Nocturnal effi-
ciency and tolerance of a demand oxygen delivery system in
COPD patients with nocturnal hypoxemia. Chest 1999;116:
22–9.
6. Yaeger ES, Goodman S, Hoddes E, et al. Oxygen the-
rapy using pulse and continuous flow with a trans-
tracheal catheter and a nasal cannula. Chest 1994;106:
854–60.
7. Butland RJA, Pang J, GE R, et al. Two- , six- , and 12-min
walking tests in respiratory disease. Br Med J 1982;284:
1607–8.
8. Wilson RC, Jones PW. A comparison of the visual ana-
logue scale and modified Borg scale for the measure-
ment of dyspnoea during exercise. Clin Sci 1989;76:
277–82.
9. Robert D, Leger P, Perrin F. Evaluation of an intermittent
flow oxygen system. Bull Eur Physiopathol Respir
1986;22:315–8.
10. Tiep BL, Christopher KL, Spofford BT, et al. Pulsed nasal and
transtracheal oxygen delivery. Chest 1990;97:364–8.
11. Braun SR, Spratt G, Scott GC, et al. Comparison of six oxygen
delivery systems for COPD patients at rest and during
exercise. Chest 1992;102:694–8.
12. Bliss PL, McCoy RW, Adams AB. A bench study comparison of
demand oxygen delivery systems and continuous flow
oxygen. Respir Care 1999;44:925–31.
13. Bower JS, Brook CJ, Zimmer K, et al. Performance of a
demand oxygen saver system during rest, exercise, and
sleep in hypoxemic patients. Chest 1988;94:77–80.
14. Garrod R, Bestall JC, Paul EA, et al. Evaluation of pulsed
dose oxygen delivery during exercise in patients with severe
chronic obstructive pulmonary disease. Thorax
1999;54:242–4.
15. Hagarty EM, Skorodin MS, Langbein WE, et al. Comparison of
three oxygen delivery systems during exercise in hypoxemic
patients with chronic obstructive pulmonary disease. Am
J Respir Crit Care Med 1997;155:893–8.
16. Senn S, Wanger J, Fernandez E, et al. Efficacy of a pulsed
oxygen delivery device during exercise in patients with
chronic respiratory disease. Chest 1989;96:467–72.
ARTICLE IN PRESS
Comparison of four demand oxygen delivery systems 943
17. Carter R, Tashkin D, Djahed B, et al. Demand oxygen
delivery for patients with restrictive lung disease. Chest
1989;96:1307–11.
18. Roberts CM, Bell J, Wedzicha JA. Comparison of the efficacy
of a demand oxygen delivery system with continuous low
flow oxygen in subjects with stable COPD and severe oxygen
desaturation on walking. Thorax 1996;51:831–4.
19. Segard B, Muir JF, Bedicam JM, et al. ,La qualit !e de
l’oxyg!ene dispens !ee par des dispositifs utilisant des valves
!economisatrices d’oxygene. Une !etude multicentrique. Rev
Mal Respir 1992;9:197–204.
20. Kerby GR, O’Donohue WJ, Romberger DJ, et al. Clinical
efficacy and cost benefit of pulse flow oxygen in hospitalized
patients. Chest 1990;97:369–72.
ARTICLE IN PRESS
944 C. Fuhrman et al.
